[
  {
    "ts": null,
    "headline": "GS Equity Income Fund: Q3 2025 Witnesses Fundamental Strength And Expansive Margin Opportunities",
    "summary": "GS Equity Income Fund underperformed in Q3. Discover key contributors like Oracle & J&J, and detractors Kenvue & Honeywell. Click here to read the full report.",
    "url": "https://finnhub.io/api/news?id=1be27c9d9dcbf5d7b38a82b075097f50c391a55eea229761631307c2aba05e96",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765317000,
      "headline": "GS Equity Income Fund: Q3 2025 Witnesses Fundamental Strength And Expansive Margin Opportunities",
      "id": 137744841,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2231574166/image_2231574166.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "GS Equity Income Fund underperformed in Q3. Discover key contributors like Oracle & J&J, and detractors Kenvue & Honeywell. Click here to read the full report.",
      "url": "https://finnhub.io/api/news?id=1be27c9d9dcbf5d7b38a82b075097f50c391a55eea229761631307c2aba05e96"
    }
  },
  {
    "ts": null,
    "headline": "Cancer Study Buoys These Small Biotechs",
    "summary": "Terns Pharmaceuticals shares jumped as much as 50% on news that cancer cell counts fell over 99% in nearly three-fourths of leukemia patients treated with the firm’s once-daily pill.",
    "url": "https://finnhub.io/api/news?id=f8b874e78ed4b9a4203431d52389ffe857faefcbb91d027754e6ce2b2d3d26a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765312260,
      "headline": "Cancer Study Buoys These Small Biotechs",
      "id": 137748590,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Terns Pharmaceuticals shares jumped as much as 50% on news that cancer cell counts fell over 99% in nearly three-fourths of leukemia patients treated with the firm’s once-daily pill.",
      "url": "https://finnhub.io/api/news?id=f8b874e78ed4b9a4203431d52389ffe857faefcbb91d027754e6ce2b2d3d26a9"
    }
  },
  {
    "ts": null,
    "headline": "Jamie Dimon taps Jeff Bezos, Michael Dell, and Ford CEO Jim Farley to advise JPMorgan’s $1.5 trillion national security initiative",
    "summary": "Former military commanders, politicians, and one of Warren Buffett’s top stock pickers are also joining the advisory group.",
    "url": "https://finnhub.io/api/news?id=aa7915e7f45d9ae39405be99734a0e05082634ddbd79aa3a208519163647e9ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765309765,
      "headline": "Jamie Dimon taps Jeff Bezos, Michael Dell, and Ford CEO Jim Farley to advise JPMorgan’s $1.5 trillion national security initiative",
      "id": 137749869,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Former military commanders, politicians, and one of Warren Buffett’s top stock pickers are also joining the advisory group.",
      "url": "https://finnhub.io/api/news?id=aa7915e7f45d9ae39405be99734a0e05082634ddbd79aa3a208519163647e9ea"
    }
  },
  {
    "ts": null,
    "headline": "Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal",
    "summary": "Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.",
    "url": "https://finnhub.io/api/news?id=18c6c518fd9ae16d7e56818f8e62791ae026a9ff69d57b0ee4933283232cc6a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765305600,
      "headline": "Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal",
      "id": 137749832,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.",
      "url": "https://finnhub.io/api/news?id=18c6c518fd9ae16d7e56818f8e62791ae026a9ff69d57b0ee4933283232cc6a8"
    }
  },
  {
    "ts": null,
    "headline": "1 Major Factor Behind the Healthcare Sector's Recent Surge",
    "summary": "Blockbuster drugs are a major driver of the growth of healthcare stocks.",
    "url": "https://finnhub.io/api/news?id=961fc079ac660d5adfeab69920ace9a1d553cc860668ba87c4183f0a08ab4342",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765296917,
      "headline": "1 Major Factor Behind the Healthcare Sector's Recent Surge",
      "id": 137741749,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Blockbuster drugs are a major driver of the growth of healthcare stocks.",
      "url": "https://finnhub.io/api/news?id=961fc079ac660d5adfeab69920ace9a1d553cc860668ba87c4183f0a08ab4342"
    }
  },
  {
    "ts": null,
    "headline": "The 5 Best S&P 500 Dividend Aristocrat Stocks to Buy Before 2026",
    "summary": "Given the potential for a sizable sell-off, it makes sense for investors to move to S&P 500 Dividend Aristocrat stocks like these now.",
    "url": "https://finnhub.io/api/news?id=54d960bdc422cae225618656f012ad261c12f7640f62c0b860d6f11d25732814",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765293533,
      "headline": "The 5 Best S&P 500 Dividend Aristocrat Stocks to Buy Before 2026",
      "id": 137742584,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Given the potential for a sizable sell-off, it makes sense for investors to move to S&P 500 Dividend Aristocrat stocks like these now.",
      "url": "https://finnhub.io/api/news?id=54d960bdc422cae225618656f012ad261c12f7640f62c0b860d6f11d25732814"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Says Tecvayli With Darzalex Faspro Cuts Risk of Death in Multiple Myeloma",
    "summary": "Johnson & Johnson (JNJ) said Tuesday that new data from a phase 3 study showed the combination of Te",
    "url": "https://finnhub.io/api/news?id=bb61dd93e4ddf773ab975000505ce2e1b0cc342aa23b3217a7e953e9b11d14d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765292997,
      "headline": "Johnson & Johnson Says Tecvayli With Darzalex Faspro Cuts Risk of Death in Multiple Myeloma",
      "id": 137742594,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) said Tuesday that new data from a phase 3 study showed the combination of Te",
      "url": "https://finnhub.io/api/news?id=bb61dd93e4ddf773ab975000505ce2e1b0cc342aa23b3217a7e953e9b11d14d3"
    }
  },
  {
    "ts": null,
    "headline": "Cooper Companies Growth Is Underwhelming",
    "summary": "The Cooper Companies, Inc. is rated a Sell due to underperformance versus industry peers and an unfavorable valuation profile. Read more on COO stock here.",
    "url": "https://finnhub.io/api/news?id=469c49d977956ea3f8954504a7db4eb6e2c48b69c150cdf90fc74af239d65975",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765292294,
      "headline": "Cooper Companies Growth Is Underwhelming",
      "id": 137743290,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/683733883/image_683733883.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "The Cooper Companies, Inc. is rated a Sell due to underperformance versus industry peers and an unfavorable valuation profile. Read more on COO stock here.",
      "url": "https://finnhub.io/api/news?id=469c49d977956ea3f8954504a7db4eb6e2c48b69c150cdf90fc74af239d65975"
    }
  },
  {
    "ts": null,
    "headline": "Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma",
    "summary": "Teclistamab and daratumumab subcutaneous (SC) combination led to a statistically significant progression-free survival and overall survival advantage compared to standard treatment after three years of follow-up1 Combination regimen granted Breakthrough Therapy Designation by U.S. FDA BEERSE, BELGIUM, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI®▼ (teclistamab) plus DARZAL",
    "url": "https://finnhub.io/api/news?id=d54a38c08fddc05d8dac72743bda1b12db8b0f5d94d081d3383da1f0e2411df9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765290060,
      "headline": "Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI®▼ (teclistamab) plus DARZALEX® (daratumumab) subcutaneous formulation as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma",
      "id": 137740111,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Teclistamab and daratumumab subcutaneous (SC) combination led to a statistically significant progression-free survival and overall survival advantage compared to standard treatment after three years of follow-up1 Combination regimen granted Breakthrough Therapy Designation by U.S. FDA BEERSE, BELGIUM, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI®▼ (teclistamab) plus DARZAL",
      "url": "https://finnhub.io/api/news?id=d54a38c08fddc05d8dac72743bda1b12db8b0f5d94d081d3383da1f0e2411df9"
    }
  },
  {
    "ts": null,
    "headline": "Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma",
    "summary": "Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as early as second line for patients with relapsed/refractory multiple myeloma (RRMM). Results show an 83% reduction in the risk of disease progression or death compared to standard regimens at nearly three-years follow-up (hazard",
    "url": "https://finnhub.io/api/news?id=63bd6da4b854c3ff365304c36e70e1bf8dff06eaa3a388645af64fe3e15957f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765284240,
      "headline": "Unprecedented results from the Phase 3 MajesTEC-3 study support TECVAYLI® plus DARZALEX FASPRO® as a potential standard of care as early as second line for patients with relapsed/refractory multiple myeloma",
      "id": 137740112,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as early as second line for patients with relapsed/refractory multiple myeloma (RRMM). Results show an 83% reduction in the risk of disease progression or death compared to standard regimens at nearly three-years follow-up (hazard",
      "url": "https://finnhub.io/api/news?id=63bd6da4b854c3ff365304c36e70e1bf8dff06eaa3a388645af64fe3e15957f2"
    }
  }
]